IF 3.8 3区医学

Respiration Pub Date : 2025-07-30 DOI: 10.1159/000547705

Manlio Milanese, Alessandro Cavaliere, Giovanni Cavallaro, Luca Corti, Alessandra Longagna, Amatore Morando, Monica Cirone

{"title":"COPD case finding. Severity Grade at First Spirometry and Ongoing Therapy 12 Months After Initial Diagnosis.","authors":"Manlio Milanese, Alessandro Cavaliere, Giovanni Cavallaro, Luca Corti, Alessandra Longagna, Amatore Morando, Monica Cirone","doi":"10.1159/000547705","DOIUrl":"https://doi.org/10.1159/000547705","url":null,"abstract":"Aim: Approximately 30% of COPD diagnoses at first Spirometry are already at GOLD 3-4 grade of severity based on airflow obstruction with a FEV1<50% of predicted, in the more severe and resource consuming group. Therefore, as improving early COPD diagnosis, ideally at GOLD 1 grade (reported as <20%), is a strategic target, we promoted a quality-controlled Spirometry in Primary Care setting on subjects at risk for COPD (with smoking habits ≥15 pack/years).Methods: Subjects with a post bronchodilator FEV1/FVC <0.7 were consecutively enrolled in an Observational Study (STructured Efficient E-Tracking, STREET project) aiming to record ongoing COPD therapy after 12 months, and Medication Possession Ratio (MPR).Results: Of the 397 enrolled subjects, only 15% were in GOLD 1 grade. When reporting ongoing therapy prescribed by GPs at 12 months it was of interest that a) a short-acting Agonist (SA) as needed only was prescribed in 72% of GOLD 1 COPD subjects (85% with an mMRC≤1, class A), b) a Long-Acting Beta Agonist (LABA)/Inhaled Corticosteroid (ICS) combination was prescribed in 21% of GOLD 2-3 COPD subjects, although without any exacerbation (class A or B). When checking adherence to prescribed therapy, an MPR≥80% was detected in less than 30% of subjects at GOLD 1-3 grade.Conclusions: The main findings of our study are that a) about 80% of COPD subjects underwent spirometry for the first time too late, at GOLD 2-3 grade, b) 21% of those at this grade were prescribed a LABA/ICS combination not compliant with the GOLD document, and c) adherence to prescribed therapy was low at GOLD grade 1-3.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-15"},"PeriodicalIF":3.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Diagnostic Bronchoscopy Single-Arm Trials Using an Advanced Optimization Approach for Indirect Comparisons with Partial Individual Patient Data. 诊断性支气管镜单臂试验使用先进的优化方法与部分个体患者数据进行间接比较。

IF 3.8 3区医学

Respiration Pub Date : 2025-07-29 DOI: 10.1159/000547686

Anil Vachani, Septimiu Murgu, Fabien Maldonado, Balaji Laxmanan, Tony B Amos, Meijia Zhou, Faisal Khan, Gustavo Cumbo-Nacheli, Joseph Seaman, Pranjal Tewari, Stephen Johnston, Iftekhar Kalsekar, Barbara H Johnson

{"title":"Comparison of Diagnostic Bronchoscopy Single-Arm Trials Using an Advanced Optimization Approach for Indirect Comparisons with Partial Individual Patient Data.","authors":"Anil Vachani, Septimiu Murgu, Fabien Maldonado, Balaji Laxmanan, Tony B Amos, Meijia Zhou, Faisal Khan, Gustavo Cumbo-Nacheli, Joseph Seaman, Pranjal Tewari, Stephen Johnston, Iftekhar Kalsekar, Barbara H Johnson","doi":"10.1159/000547686","DOIUrl":"https://doi.org/10.1159/000547686","url":null,"abstract":"Introduction: The diagnostic yield of lung biopsy modalities is often compared using data from single-arm studies. These comparisons are biased due to differences in study populations, institutional practices, and diagnostic yield definitions. While individual patient data may be useful to account for some of these co-variables, individual patient data may only be available for one study. What is the difference in the primary outcome between two single-arm studies that utilized different bronchoscopy technologies?Methods: A MAIC analysis was performed comparing individual patient data from a retrospective multicenter cohort of consecutive RAB procedures to aggregate patient data in a prospective, multicenter clinical study of ENB procedures. The diagnostic yield was first calculated with the definition used in the comparator study, determined at 12 months after initial biopsy, with lost to follow-up excluded from the denominator (Method 1), and secondly with a strict definition, determined at the time of bronchoscopy and non-specific benign findings excluded. (Method 2).Results: Using Method 1, the weighted diagnostic yield for RAB (87.1%) was significantly higher than for ENB (72.9%) (P<0.001). Using Method 2, the weighted diagnostic yield for RAB (64.9%) was also significantly higher than for ENB (50.6%) (P=0.001).Conclusions: An optimization-based weighting approach for indirect comparisons between single arm studies confirmed a significantly higher diagnostic yield for RAB compared to ENB. When using method 2, it was demonstrated that various factors significantly influence the diagnostic yield of RAB, highlighting the need for balancing to mitigate confounding effects, and ideally, randomized controlled trials.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-18"},"PeriodicalIF":3.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144744492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of cranial electrotherapy stimulation in patients with post COVID-19 condition on anxiety symptoms - a randomised controlled trial. 颅电刺激对COVID-19后患者焦虑症状的影响——一项随机对照试验

IF 3.5 3区医学

Respiration Pub Date : 2025-07-24 DOI: 10.1159/000547385

Daniela Kroll, Rainer Gloeckl, Tessa Schneeberger, Inga Jarosch, Isabel Klefenz, Wolfgang Hitzl, Andreas R Koczulla

{"title":"Effects of cranial electrotherapy stimulation in patients with post COVID-19 condition on anxiety symptoms - a randomised controlled trial.","authors":"Daniela Kroll, Rainer Gloeckl, Tessa Schneeberger, Inga Jarosch, Isabel Klefenz, Wolfgang Hitzl, Andreas R Koczulla","doi":"10.1159/000547385","DOIUrl":"https://doi.org/10.1159/000547385","url":null,"abstract":"Introduction People with post-COVID condition (PCC) suffer from a wide range of symptoms, including anxiety. Studies have already shown that cranial electrical stimulation (CES) has a positive effect on anxiety in anxious people. This randomised, controlled, double-blind, single-centre pilot study aimed to investigate the effects of CES as an adjunctive therapy during a rehabilitation on anxiety symptoms in people with PCC. Methods Adults with PCC were randomised to an intervention group with rehabilitation and (CES) (100μA) or a control group with rehabilitation and sham stimulation. CES was applied via electrodes to the earlobes for 60 minutes daily for 3 weeks. The Beck Anxiety Inventory (BAI) score was collected at baseline and at discharge. Results Forty people with PCC completed the trial. We found that both groups with (n=20) and without CES (n=20) improved significantly in terms of change in the BAI score (CESgroup: p=0.037; shamgroup : p=0.018), with no difference between groups (p=0.82). In a subgroup analysis of anxious patients only (BAI:≥16 pts, baseline score), both groups (CESanxious: n=10, shamanxious: n=10), significantly improved the BAI-score (CESanxious: p=0.008; shamanxious: p=0.002) with no difference between groups (p=0.69). Conclusion This study suggests that CES had no additional benefit on anxiety symptoms during rehabilitation in people with PCC.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-12"},"PeriodicalIF":3.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EUROPEAN CONGRESS FOR BRONCHOLOGY AND INTERVENTIONAL PULMONOLOGY 2025 (ECBIP2025), LISBON, PORTUGAL, 8-10 MAY 2025: Abstracts. 2025年欧洲支气管学和介入肺病学大会（ECBIP2025），里斯本，葡萄牙，2025年5月8-10日：摘要。

IF 3.5 3区医学

Respiration Pub Date : 2025-07-22 DOI: 10.1159/000546933

Antonio Bugalho

引用次数: 0

Pilot Evaluation of Functional Lung Imaging via X-ray Velocimetry (XV) for the Assessment of Regional Ventilation in Severe Lung Disease. x线测速仪（XV）对重度肺部疾病局部通气评估的功能肺成像的初步评价

IF 3.5 3区医学

Respiration Pub Date : 2025-07-18 DOI: 10.1159/000547110

Gregory Snell, Bronwyn Levvey, Kris Nilsen, Glen Westall, Piraveen Pirakalathanan, Jason Kirkness, Trishul Siddharthan, Andreas Fouras, Nina Eikelis

{"title":"Pilot Evaluation of Functional Lung Imaging via X-ray Velocimetry (XV) for the Assessment of Regional Ventilation in Severe Lung Disease.","authors":"Gregory Snell, Bronwyn Levvey, Kris Nilsen, Glen Westall, Piraveen Pirakalathanan, Jason Kirkness, Trishul Siddharthan, Andreas Fouras, Nina Eikelis","doi":"10.1159/000547110","DOIUrl":"https://doi.org/10.1159/000547110","url":null,"abstract":"Introduction: Standard methods for diagnosing lung diseases are sub-optimal in detecting regional disease. X-ray Velocimetry (XV), a novel functional lung imaging technology, holds the potential to uncover unique patterns of regional lung ventilation. This study aims to explore the application of XV in subjects with severe respiratory diseases to determine if there are regional ventilation differences, and to compare the regional ventilation metrics with pulmonary function tests (PFT).Methods: In this proof-of-concept study, XV and PFT measurements were performed in subjects with severe lung disorders, referred for lung transplantation and compared with healthy controls. XV utilized fluoroscopic lung images of tidal breathing co-registered to each subject's CT chest scan to quantify voxel-wise tidal ventilation. The XV measurements included ventilation heterogeneity (VH), mean specific ventilation (MSV), and low ventilation region (LVR).Results: 40 subjects (59.3 years; 45% females) with severe lung disease were compared to 8 healthy controls (44.8 years, 25% females). XV metrics were different between those with severe lung disease and healthy controls (MSV: 0.099±0.03 vs 0.194±0.03; VH: 73.1±19.2 vs 49.7±11.2; LVR: 53.5±17.8 vs 11.4±2.7, p<0.01). There were negative, strong correlations for LVR with spirometric measurements of airflow limitation (FEV1 and FEV1/FVC) and trapping (RV/TLC). In addition, XV imaging highlighted regional ventilation changes at an individual- and group-level for subjects with obstructive and non-obstructive lung disease.Conclusion: In patients with end-stage lung disease, XV was shown to highlight low ventilation regions that correlate with airflow limitation and trapping, and demonstrate disease-specific variations in regional ventilation that warrant further investigation.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-17"},"PeriodicalIF":3.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Baricitinib for acute exacerbation in idiopathic interstitial pneumonias: A preliminary study using propensity score matching. Baricitinib治疗特发性间质性肺炎急性加重：一项使用倾向评分匹配的初步研究。

IF 3.5 3区医学

Respiration Pub Date : 2025-07-10 DOI: 10.1159/000547356

Hideaki Yamakawa, Shintaro Sato, Hiroki Ohta, Kenji Kusano, Moe Nomaki, Rie Kawabe, Chisa Uzuka, Hiroki Sasaki, Masako Amano, Tamiko Takemura, Jun Araya, Hidekazu Matsushima

{"title":"Baricitinib for acute exacerbation in idiopathic interstitial pneumonias: A preliminary study using propensity score matching.","authors":"Hideaki Yamakawa, Shintaro Sato, Hiroki Ohta, Kenji Kusano, Moe Nomaki, Rie Kawabe, Chisa Uzuka, Hiroki Sasaki, Masako Amano, Tamiko Takemura, Jun Araya, Hidekazu Matsushima","doi":"10.1159/000547356","DOIUrl":"https://doi.org/10.1159/000547356","url":null,"abstract":"Background and objective: Acute exacerbation of interstitial lung disease (AE-ILD) is a life-threatening complication for which there are only limited treatment options, with essentially no established treatment options. Janus kinase (JAK) inhibitors, such as baricitinib, have recently emerged as potential therapeutic candidates for severe and progressive forms of ILD. This study aimed to evaluate the efficacy and safety of baricitinib in patients with AE-ILD associated with idiopathic interstitial pneumonias (IIPs).Methods: This retrospective cohort study included patients with IIPs who experienced AE-ILD, and were admitted to a single tertiary care center. Patients treated with baricitinib (Dec 2022-Jun 2024) were compared with historical controls (Jan 2021-Nov 2022). Propensity score matching (PSM) was conducted using age, PaO₂/FiO₂ ratio, and fibrosis score. The primary outcome was overall survival; secondary outcomes included 90-day survival and adverse events.Results: After PSM, 17 patients were analyzed in each group. The 90-day survival rate in the baricitinib group (82.4%) was significantly higher than in the control group (52.9%, P = 0.049), while longer-term survival did not differ to a statistically significant extent. Baricitinib was well tolerated, with only mild adverse events observed. A trend toward improved 90-day survival was also noted with anti-fibrotic therapy administered during AE-ILD (P = 0.089).Conclusions: Baricitinib may improve short-term survival in AE-ILD and was well tolerated in the acute phase. Its dual JAK1/2 inhibition suggests both anti-inflammatory and antifibrotic potential. Further prospective studies are needed to confirm these findings and explore combination therapies.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-25"},"PeriodicalIF":3.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum. 勘误表。

IF 3.5 3区医学

Respiration Pub Date : 2025-07-07 DOI: 10.1159/000546778

引用次数: 0

Increased Risk of Tuberculosis Disease in Lung Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Retrospective Multicenter Study. 接受免疫检查点抑制剂治疗的肺癌患者结核病风险增加：一项回顾性多中心研究

IF 3.5 3区医学

Respiration Pub Date : 2025-07-05 DOI: 10.1159/000547109

Yeonhee Park, Jinsoo Min, Jeong Uk Lim, Chang Dong Yeo, Hye Seon Kang, Joon Young Choi, Kyu Yean Kim, Seung Hoon Kim, Ji Won Park

{"title":"Increased Risk of Tuberculosis Disease in Lung Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Retrospective Multicenter Study.","authors":"Yeonhee Park, Jinsoo Min, Jeong Uk Lim, Chang Dong Yeo, Hye Seon Kang, Joon Young Choi, Kyu Yean Kim, Seung Hoon Kim, Ji Won Park","doi":"10.1159/000547109","DOIUrl":"https://doi.org/10.1159/000547109","url":null,"abstract":"Introduction: The introduction of immune checkpoint inhibitor (ICI) therapy in lung cancer has improved survival rates, leading to its widespread use. However, there has been a recent increase in case reports of tuberculosis (TB) disease occurrence following ICI treatment. The objective of this study was to ascertain whether the incidence of TB disease is elevated in the ICI group compared to the group receiving platinum-based chemotherapy among all lung cancer patients.Methods: To compare the risk of TB disease occurrence between the ICI group and the Platinum group in lung cancer patients, a retrospective study was conducted using the clinical data warehouse platform of eight university hospitals affiliated with the Catholic Medical Center in South Korea.Results: Out of a total of 7,980 patients, those meeting the exclusion criteria were excluded, 991 were categorized into the ICI group, and 3,646 were classified into the Platinum group. The TB disease incidence rate was significantly higher in the ICI group (4.46 per 1,000 person-years) than in the platinum group (1.12 per 1,000 person-years), with a rate ratio (RR) of 3.98 (95% CI: 1.58-10.00; p = 0.003). Multivariable analysis confirmed ICI therapy as the sole factor significantly associated with TB disease occurrence (adjusted HR: 3.701 95% CI: 1.467-9.333; p = 0.006).Conclusion: Treatment with ICI in lung cancer patients was associated with a statistically significant increase in the risk of TB disease occurrence compared to conventional platinum-based chemotherapy. Therefore, particularly in patients treated with ICI therapy, prompt respiratory sample tests should be performed for early TB disease diagnosis when new lung lesions are identified.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-16"},"PeriodicalIF":3.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Become Known: Through Scientific Publications or Social Media Activity? 如何成名：通过科学出版物还是社交媒体活动？

IF 3.5 3区医学

Respiration Pub Date : 2025-07-05 DOI: 10.1159/000547252

Felix Jf Herth, Franziska Trudzinski

引用次数: 0

Fluid restriction in patients with pulmonary arterial hypertension and right heart failure. 肺动脉高压和右心衰患者的液体限制。

IF 3.5 3区医学

Respiration Pub Date : 2025-07-05 DOI: 10.1159/000546769

Nicola Benjamin, Carolin Resag, Panagiota Xanthouli, Satenik Harutyunova, Christina Eichstaedt, Benjamin Egenlauf, Ekkehard Grünig

{"title":"Fluid restriction in patients with pulmonary arterial hypertension and right heart failure.","authors":"Nicola Benjamin, Carolin Resag, Panagiota Xanthouli, Satenik Harutyunova, Christina Eichstaedt, Benjamin Egenlauf, Ekkehard Grünig","doi":"10.1159/000546769","DOIUrl":"https://doi.org/10.1159/000546769","url":null,"abstract":"Background: In pulmonary arterial hypertension (PAH) right heart (RH) failure is associated with high mortality and poor prognosis. The objective of this cohort study was to assess, whether reduction of fluid-intake is associated with RH size and clinical outcome in PAH patients.Methods: A retrospective, exploratory analysis of patients with invasively diagnosed PAH and signs of fluid retention who were routinely clinically monitored for 8.4±5.3 months including fluid-uptake and signs of RH failure was performed. Patients were advised to reduce fluid-uptake to a maximum of 2 litres per day (l/d) according to clinical routine. Clinical characteristics of patients with normal fluid-intake <2l/d vs. high fluid-intake ≥2l/d and patients who reduced vs. patients with increased fluid-intake during follow-up were compared. Furthermore, the influence of hospitalization due to fluid overload and for treatment with iv diuretics at baseline and fluid-intake on survival and time to clinical worsening (TTCW) were investigated.Results: Out of 66 patients with signs of fluid retention at baseline (normal fluid-intake <2l/day, n=16; high fluid-intake ≥2l/d, n=50), 21 presented with hospitalization due to fluid overload, which was significantly associated with worse survival (p=0.004) and TTCW (p<0.001). During follow-up patients who reduced fluid-intake <2l/day presented with in trend reduced right ventricular area (p=0.051) and longer TTCW (p=0.007). Hospitalisation due to fluid-overload and fluid-intake during follow-up were independent predictors of TTCW.Conclusions: Restriction of fluid-intake in PAH patients was highly effective and associated with significantly longer TTCW. Further evaluation of fluid restriction in PAH patients is needed in larger studies.","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-25"},"PeriodicalIF":3.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Respiration最新文献